The Trump administration has targeted $4 billion in cuts to “indirect” costs for NIH research grants. Those funds, typically ...

Piper Sandler, a well-known investment firm, increased its price target on shares of Amgen (NASDAQ:AMGN) to $329.00, up from the previous target of $310.00. The firm has maintained its Overweight ...

If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the First Trust NYSE Arca Biotechnology ETF (FBT), a passively managed exchange ...

Arrowhead Pharmaceuticals recently received the FDA NDA acceptance for Plozasiran. Read why I believe ARWR stock could be a ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

TScan Therapeutics is developing engineered T cell receptor therapies, with TSC-101 targeting HA-2 for acute leukemia. See ...

To illustrate that point, let's discuss two stocks in the biotech industry that have moved in opposite directions so far this ...

President Trump’s first term was bad,” he said, “but nobody knows what’s coming. … This is truly nationalism at its worst, because he won on the campaign [largely] to protect American jobs, claiming ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Could you tell me about the firm? Mr. Kennedy: AllSource is a firm that focuses on high-net-worth and ultra-high-net-worth families, and we specialize in alternative investments. We like to say we ...

With the Canadian economy experiencing a contraction in November and a recent interest rate cut by the Bank of Canada due to tariff uncertainties, investors are navigating a complex landscape. In such ...

Breakthrough research and investor enthusiasm prompted Cullinan Therapeutics to redirect one of its cancer programs toward ...